ESSM - Regen Lab Webinar Series

Jour(s)

:

Heure(s)

:

Minute(s)

:

Seconde(s)

We are pleased to invite you to the next session of the ESSM Webinar Series 2025, proudly hosted in collaboration with RegenLab.

A 360° Perspective on Platelet-Rich Plasma (PRP) Therapy to explore its role in the management of:
• Female Sexual Dysfunction (FSD)
• Stress Urinary Incontinence (SUI)
• Genitourinary Symptoms of Menopause (GUSM)

This session brings together expert insights into the regenerative applications of PRP in female sexual health, combining clinical evidence with real-world experience.

Moderators

Dr Sam Ward
Uro-Andrology, MD
Brussels, Belgium

Prof Dr Daniar Osmonov
Uro-Andrology
Germany

Speakers

Meletios Nigdelis
Resident in Obstetrics and Gynceology
Germany

Sarah Berndt
Biomedical & Pharmaceutical Sciences, PhD Geneva, Switzerland

Antonella de Ponte Davi
Obstetrics & Gynaecology, MD 
Barcelona, Spain 

Program

20:00-20:05 | Welcome and Introduction

Dr Sam Ward and Prof Dr Daniar Osmonov (ESSM Chairs)
Relevance of the topic in the field of Sexual Medicine, session objectives, and introduction of Speakers

20:05-20:25 | Part 1 | Evidence, learnings, and challenges from the literature and / or the lab

Meletios Nigdelis (MD, Universitätsklinikum des Saarlandes – UKS, Homburg, Germany)
Publication presentation : “Efficacy and Safety of Platelet-Rich Plasma Injections for the Treatment of Female Sexual Dysfunction and Stress Urinary Incontinence: A Systematic Review”, co-author.

Sarah Berndt (PhD, Hospital Universitaire de Genève – HUGE, Geneva, Switzerland)
Research findings in cell culture of Vaginal Explants exposed to autologous blood-derived products: analysing the regenerative effects (Ex-vivo)

20:25-20:45 | Part 2 | Clinical practice and future research 

Antonella de Ponte Davi (MD, Hospital Unversitari Dexeus, Barcelona, Spain)
Considerations and possibilities for treating GUSM and related disorders with PRP+HA and review of clinical response

20:45-21:00 | Part 3 | Moderated Discussion followed by Q&A and closure

About Us

Since 2003, Regen Lab SA has specialized in designing and manufacturing high-quality medical devices for cell therapies and the preparation of autologous platelet-rich plasma (PRP) from the patient's own blood for bedside procedures.

Milestones

2003 - Foundation
2010 - RegenKit first approval in bone graft
2013 - A new state-of-theart laboratory in Lausanne
2014 - Cellular Matrix first approval
2015 - Launch of Cellular Matrix in Europe

Vision

Founded in 2003, Regen Lab has become a global reference thanks to its commitment to innovation, quality, and the effectiveness of its therapeutic solutions. Here’s how we have transformed the medical landscape over the past two decades.

RegenPRP™

RegenPRP™ is a medical treatment that uses platelet-rich plasma from the patient's own blood to enhance and tissue regeneration.

RegenPRP™ - HA

RegenPRP™ - HA combination is an innovative treatment combining platelet-rich plasma (PRP) and hyaluronic acid to improve tissue regeneration and healing.

RegenPRP™ - ATS

RegenPRP™ combined with ATS (Autologous Thrombin Serum) is an advanced approach to tissue regeneration that uses autologous thrombin-enriched platelet-rich plasma (PRP) to maximise healing effects.

RegenExtracell®

RegenExtracell is an innovative tissue regeneration treatment using an extracellular matrix enriched with platelet-rich plasma (PRP).

Hyaluronic Acid

Coming Soon

Regulatory

Manufacturers of medical devices based outside the EU must designate an Authorized Representative (EC-REP) established within the EU in order to meet the CE requirements for placing medical devices on the EU market.

Quality Management

Regen Lab Quality System Management ensures the consistency of our products quality in total GMP compliance.

Our production facility rooms atmosphere is monitored to satisfy non-pyrogenic medical devices manufacturing.

Patents

As a leader in the PRP&HA regenerative field and as an innovation-driven company, Regen Lab SA has devoted important resources since 2004 to put on the market pioneering and diversified products constituting a complete set of tools/technologies for the medical community.